The Military Orchestra of the People's Liberation Army will go to Vietnam to participate in the celebration. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, released a message on the recent military-related issues: At the invitation of the Ministry of National Defense of Vietnam, the Military Orchestra of the People's Liberation Army of China will send a team to perform in Vietnam from December 14 to 23 to participate in the celebration of the 80th anniversary of the founding of the Vietnamese People's Army. This move will help deepen the traditional friendship between the Chinese and Vietnamese armed forces and expand the cultural exchanges between the two armed forces. (CCTV military)According to people familiar with the matter, Trump's advisers and officials from his newly formed government efficiency department asked him if he could abolish the Federal Deposit Insurance Corporation (FDIC).Yuejiang: It is planned to sell about 40 million H shares globally through the IPO of Hong Kong stocks. It is expected to be listed on the Hong Kong Stock Exchange on December 23, and Yuejiang announced on the Hong Kong Stock Exchange on December 13 that the company plans to sell about 40 million H shares globally, with Hong Kong public offering accounting for 5% and international offering accounting for 95%. The offer price will not be higher than HK$ 20.80 per offering share, and it is currently expected to be not lower than HK$ 18.80 per offering share, with 200 shares per lot. It is expected that the shares will start trading on the Stock Exchange at 9: 00 am on Monday, December 23, 2024, Hong Kong time.
The A-share financing balance hit a new high of more than 9 years, and the big consumption sector broke out. According to china securities journal, on December 12, the A-share market opened lower and went higher. At the close, the Shanghai Composite Index rose by nearly 1%, the Shenzhen Composite Index rose by 1% and the Growth Enterprise Market Index rose by more than 1%. More than 3,500 stocks in the entire A-share market rose, with more than 150 stocks trading daily, and the big consumer sector broke out. The market turnover was 1.89 trillion yuan, which has exceeded 1 trillion yuan for 52 consecutive trading days, setting a new record for the A-share market. In terms of funds, Wind data shows that as of December 11th, the financing balance in the A-share market was 1,875.85 billion yuan, a record high of over 9 years. In the first three trading days of this week, the financing balance "increased three times in a row", with a cumulative increase of 22.579 billion yuan. Analysts believe that short-term ample liquidity and optimistic policy expectations are still the main support of the market. In the medium and long term, the A-share market is expected to continue to fluctuate upward under the dual promotion of policy expectations and economic trends.Britain's GFK consumer confidence index was negative 17 in December, the highest since August, and negative 18 in November. The survey estimated that it was negative 18.Thirteen companies disclosed the progress of repurchase, among which Green Energy Huichong and Ruike had the highest amount of laser repurchase plans. On December 13th, a total of 13 companies issued announcements on stock repurchase. Among them, two companies disclosed the stock repurchase plan for the first time, four companies disclosed the progress of the implementation of stock repurchase, and seven companies have completed the implementation of the repurchase plan. Judging from the initial disclosure of the repurchase plan, Green Energy Huichong and Ruike Laser have the highest amount of repurchase plans, with the planned repurchase not exceeding 1.115 million yuan and 487,900 yuan respectively. Judging from the implementation progress of repurchase, Yuanli Technology, Jiuli Special Materials and Jack have the highest share repurchase amounts, with 33.1077 million yuan, 30.9807 million yuan and 3.2323 million yuan respectively. Judging from the completed repurchase, a total of one company repurchased more than 10 million on that day. Aerospace Rainbow, Aerospace Rainbow and Guanshi Technology have completed the highest repurchase amount, with 33.2989 million yuan, 2.479 million yuan and 2.1642 million yuan respectively.
New Zealand wants to persuade the United States not to impose tariffs after Trump takes office. New Zealand Finance Minister Nicola Willis said that after US President-elect Donald Trump takes office, New Zealand should be exempted from imposing comprehensive tariffs, and asked officials to be sensible to the United States. "Our initial position was please don't do this," Willis said in an interview in Wellington. "We let diplomats show the best of New Zealand."Korean media: South Korean President Yin Xiyue tried to appoint a new defense minister. The East Asia Daily did not explain that the source reported that South Korean President Yin Xiyue tried to appoint a new defense minister, which indicated that Yin Xiyue might resume his job, although he said last week that he would let the ruling party decide how to stabilize future state affairs and his term of office. After making a public speech on Thursday, Yin Xiyue approved the 42 agendas adopted at this week's cabinet meeting. This shows that Yin Xiyue may exercise the presidential power immediately after he hinted in his speech that he had no intention of stepping down.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.
Strategy guide 12-13
Strategy guide
12-13
Strategy guide 12-13